+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Rituximab in combination with CHOP chemotherapy for the treatment of diffuse large B cell lymphoma in Japan: a retrospective analysis of 1,057 cases from Kyushu Lymphoma Study Group



Rituximab in combination with CHOP chemotherapy for the treatment of diffuse large B cell lymphoma in Japan: a retrospective analysis of 1,057 cases from Kyushu Lymphoma Study Group



International Journal of Hematology 91(2): 258-266



We performed a retrospective analysis of patients with diffuse large B cell lymphoma treated with rituximab plus CHOP (cyclophosphamide, adriamycin, vincristine and prednisone) as a first-line therapy at 22 hospitals of the Kyushu Lymphoma Study Group. During the period 1996-2005, 1,057 patients (aged 22-90 years) were analyzed. Of these, 678 were treated with CHOP, and 379 were treated with rituximab plus CHOP (R-CHOP). The complete response rate was 59.9% in the CHOP group and 67.0% in the R-CHOP group (P < 0.001). Three-year progression-free survival (PFS) and overall survival (OS) rates were significantly higher in the R-CHOP group than in the CHOP group (61.3 vs. 45.6% for PFS, P < 0.001; 68.3 vs. 54.5% for OS, P < 0.001). The International Prognostic Index was a good prognostic marker for both groups; a survival benefit of rituximab addition was found for each risk subgroup and also for both age groups (60 years). Among 345 patients who received localized radiation therapy, the adding rituximab to CHOP attenuated the survival difference between CHOP and R-CHOP groups (P = 0.104), compared with no radiation group (P < 0.001). Results of this large-scale, multicenter study confirm that rituximab plus CHOP provided a greater survival benefit than CHOP alone.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 055590091

Download citation: RISBibTeXText

PMID: 20066574

DOI: 10.1007/s12185-009-0475-2


Related references

Rituximab in combination with CHOP chemotherapy for the treatment of diffuse large B cell lymphoma in China: a 10-year retrospective follow-up analysis of 437 cases from Shanghai Lymphoma Research Group. Annals of Hematology 91(6): 837-845, 2012

Rituximab in combination with CHOP chemotherapy for the treatment of diffuse large B cell lymphoma in China a 1-year retrospective follow-up analysis of 437 cases from Shanghai Lymphoma Research Group. 2012

Successful treatment of diffuse large B-cell lymphoma following Waldenström's macroglobulinemia with CHOP chemotherapy followed by combination therapy of CHOP with rituximab. Internal Medicine 43(2): 131-134, 2004

Rituximab in combination with CHOP chemotherapy for the treatment of diffuse large B cell lymphoma in Chinese patients. Annals of Hematology 86(9): 639-645, 2007

Prognostic importance of the soluble form of IL-2 receptorα (sIL-2Rα) and its relationship with surface expression of IL-2Rα (CD25) of lymphoma cells in diffuse large B-cell lymphoma treated with CHOP-like regimen with or without rituximab: a retrospective analysis of 338 cases. Journal of Clinical and Experimental Hematopathology 53(3): 197-205, 2013

Phase II study of Rituximab in combination with CHOP chemotherapy and GMCSF in patients with previously untreated diffuse large cell lymphoma and mantle cell lymphoma. Blood 98(11 Part 2): 251b, 2001

Additional rituximab-CHOP (R-CHOP) versus involved-field radiotherapy after a brief course of R-CHOP in limited, non-bulky diffuse large B-cell lymphoma: a retrospective analysis. Korean Journal of Hematology 45(4): 253-259, 2010

Optimization of rituximab for the treatment of diffuse large B-cell lymphoma (II): extended rituximab exposure time in the SMARTE-R-CHOP-14 trial of the german high-grade non-Hodgkin lymphoma study group. Journal of Clinical Oncology 32(36): 4127-4133, 2014

Young patients with non-germinal center B-cell-like diffuse large B-cell lymphoma benefit from intensified chemotherapy with ACVBP plus rituximab compared with CHOP plus rituximab: analysis of data from the Groupe d'Etudes des Lymphomes de l'Adulte/lymphoma study association phase III trial LNH 03-2B. Journal of Clinical Oncology 32(35): 3996-4003, 2014

Prognostic Importance of the Soluble Form of Il-2 Receptor^|^alpha; (sIl-2R^|^alpha;) and its Relationship with Surface Expression of Il-2R^|^alpha; (Cd25) of Lymphoma Cells in Diffuse Large B-cell Lymphoma Treated with Chop-like Regimen with or without Rituximab : A Retrospective Analysis of 338 Cases. Journal of Clinical and Experimental Hematopathology 53(3): 197-205, 2013

CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group. Lancet. Oncology 7(5): 379-391, 2006

Irinotecan plus cisplatin and dexamethasone (ICD) combination chemotherapy for patients with diffuse large B-cell lymphoma previously treated with Rituximab plus CHOP. Cancer ChemoTherapy and Pharmacology 62(2): 299-304, 2008

A pilot study of Epratuzumab and Rituximab in combination with CHOP chemotherapy in previously untreated patients with diffuse large B-Cell lymphoma. Blood 102(11): 643a-644a, 2003

CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. New England Journal of Medicine 346(4): 235-242, 2002

Primary mediastinal large B-cell lymphoma: a retrospective analysis of rituximab and CHOP chemotherapy. Community Oncology 4(11): 673-677, 2007